These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36305188)

  • 1. Effect of weekly 17-hydroxyprogesterone caproate on small for gestational age among pregnant women with HIV in Zambia.
    Conner MG; Vwalika B; Freeman BL; Sebastião YV; Mabula-Bwalya CM; Cole SR; Stringer EM; Kasaro MP; Stringer JSA; Price JT
    AIDS; 2022 Nov; 36(14):2079-2081. PubMed ID: 36305188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
    Price JT; Vwalika B; Freeman BL; Cole SR; Mulenga HB; Winston J; Mbewe FM; Chomba E; Mofenson LM; Rouse DJ; Goldenberg RL; Stringer JSA
    BMC Pregnancy Childbirth; 2019 Feb; 19(1):81. PubMed ID: 30813934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
    Price JT; Vwalika B; Freeman BL; Cole SR; Saha PT; Mbewe FM; Phiri WM; Peterson M; Muyangwa D; Sindano N; Mwape H; Smithmyer ME; Kasaro MP; Rouse DJ; Goldenberg RL; Chomba E; Stringer JSA
    Lancet HIV; 2021 Oct; 8(10):e605-e613. PubMed ID: 34509197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.
    Della Torre M; Enakpene C; Ravangard S; DiGiovanni L; Deyo K; Whelan A; Sutherland M; Fischer J
    Am J Obstet Gynecol MFM; 2019 Nov; 1(4):100051. PubMed ID: 33345841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
    Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
    Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
    Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
    Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
    Caritis SN; Venkataramanan R; Thom E; Harper M; Klebanoff MA; Sorokin Y; Thorp JM; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Grobman WA; Mercer BM; Sciscione A; Rouse DJ; Ramin S;
    Am J Obstet Gynecol; 2014 Feb; 210(2):128.e1-6. PubMed ID: 24113254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.
    Gyamfi C; Horton AL; Momirova V; Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Meis PJ; Spong CY; Dombrowski M; Sibai B; Varner MW; Iams JD; Mercer BM; Carpenter MW; Lo J; Ramin SM; O'Sullivan MJ; Miodovnik M; Conway D;
    Am J Obstet Gynecol; 2009 Oct; 201(4):392.e1-5. PubMed ID: 19716543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy.
    Waters TP; Schultz BAH; Mercer BM; Catalano PM
    Obstet Gynecol; 2009 Jul; 114(1):45-49. PubMed ID: 19546757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
    Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
    Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials.
    Saccone G; Khalifeh A; Elimian A; Bahrami E; Chaman-Ara K; Bahrami MA; Berghella V
    Ultrasound Obstet Gynecol; 2017 Mar; 49(3):315-321. PubMed ID: 27546354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
    Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
    Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.
    Grobman WA; Thom EA; Spong CY; Iams JD; Saade GR; Mercer BM; Tita AT; Rouse DJ; Sorokin Y; Wapner RJ; Leveno KJ; Blackwell S; Esplin MS; Tolosa JE; Thorp JM; Caritis SN; Van Dorsten JP;
    Am J Obstet Gynecol; 2012 Nov; 207(5):390.e1-8. PubMed ID: 23010094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.